This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burns, J. L.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burns, J. L.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, May 2000, p. 1818-1822, Vol. 38, No. 5
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Comparison of Agar Diffusion Methodologies for Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

Jane L. Burns,1,* Lisa Saiman,2 Susan Whittier,3 Davise Larone,3,dagger Jay Krzewinski,1 Zhenling Liu,2 Steven A. Marshall,4 and Ronald N. Jones4

Department of Pediatrics, Division of Infectious Disease, University of Washington, Seattle, Washington1; Department of Pediatrics, Division of Infectious Diseases, Columbia University,2 and Department of Pathology, New York Presbyterian Hospital (Columbia Presbyterian Center),3 New York, New York; and Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa4

Received 21 July 1999/Returned for modification 22 October 1999/Accepted 8 March 2000

Pseudomonas aeruginosa is the most common pathogen infecting the lungs of patients with cystic fibrosis (CF). Improved antimicrobial chemotherapy has significantly increased the life expectancy of these patients. However, accurate susceptibility testing of P. aeruginosa isolates from CF sputum may be difficult because the organisms are often mucoid and slow growing. This study of 597 CF isolates of P. aeruginosa examined the correlation of disk diffusion and Etest (AB BIODISK, Solna, Sweden) results with a reference broth microdilution method. The rates of interpretive errors for 12 commonly used antipseudomonal antimicrobials were determined. The disk diffusion method correlated well (zone diameter versus MIC) for all of the agents tested. However, for mucoid isolates, correlation coefficients (r values) for piperacillin, piperacillin-tazobactam, and meropenem were <0.80. The Etest correlation with reference broth microdilution results (MIC versus MIC) was acceptable for all of the agents tested, for both mucoid and nonmucoid isolates. Category interpretation errors were similar for the disk diffusion and Etest methods with 0.4 and 0.1%, respectively, very major errors (false susceptibility) and 1.1 and 2.2% major errors (false resistance). Overall, both agar diffusion methods appear to be broadly acceptable for routine clinical use in susceptibility testing of CF isolates of P. aeruginosa.


* Corresponding author. Mailing address: Children's Hospital and Regional Medical Center, 4800 Sand Point Way N.E., CH-32, Seattle, WA 98105. Phone: (206) 526-2073. Fax: (206) 527-3890. E-mail: jburns{at}chmc.org.

dagger Present address: New York Presbyterian Hospital (Weill Cornell Center), New York, N.Y.


Journal of Clinical Microbiology, May 2000, p. 1818-1822, Vol. 38, No. 5
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Otto-Karg, I., Jandl, S., Muller, T., Stirzel, B., Frosch, M., Hebestreit, H., Abele-Horn, M. (2009). Validation of Vitek 2 Nonfermenting Gram-Negative Cards and Vitek 2 Version 4.02 Software for Identification and Antimicrobial Susceptibility Testing of Nonfermenting Gram-Negative Rods from Patients with Cystic Fibrosis. J. Clin. Microbiol. 47: 3283-3288 [Abstract] [Full Text]  
  • Strateva, T., Petrova, G., Perenovska, P., Mitov, I. (2009). Bulgarian cystic fibrosis Pseudomonas aeruginosa isolates: antimicrobial susceptibility and neuraminidase-encoding gene distribution. J Med Microbiol 58: 690-692 [Full Text]  
  • Mazzariol, A., Aldegheri, M., Ligozzi, M., Lo Cascio, G., Koncan, R., Fontana, R. (2008). Performance of Vitek 2 in Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa Isolates with Different Mechanisms of {beta}-Lactam Resistance. J. Clin. Microbiol. 46: 2095-2098 [Abstract] [Full Text]  
  • Oberhardt, M. A., Puchalka, J., Fryer, K. E., Martins dos Santos, V. A. P., Papin, J. A. (2008). Genome-Scale Metabolic Network Analysis of the Opportunistic Pathogen Pseudomonas aeruginosa PAO1. J. Bacteriol. 190: 2790-2803 [Abstract] [Full Text]  
  • Juretschko, S., LaBombardi, V. J., Lerner, S. A., Schreckenberger, P. C., and the Pseudomonas AST Study Group, (2007). Accuracies of {beta}-Lactam Susceptibility Test Results for Pseudomonas aeruginosa with Four Automated Systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2). J. Clin. Microbiol. 45: 1339-1342 [Abstract] [Full Text]  
  • Goss, C. H, Burns, J. L (2007). Exacerbations in cystic fibrosis {middle dot} 1: Epidemiology and pathogenesis. Thorax 62: 360-367 [Abstract] [Full Text]  
  • Zhou, J., Garber, E., Desai, M., Saiman, L. (2006). Compliance of Clinical Microbiology Laboratories in the United States with Current Recommendations for Processing Respiratory Tract Specimens from Patients with Cystic Fibrosis. J. Clin. Microbiol. 44: 1547-1549 [Abstract] [Full Text]  
  • Sader, H. S., Fritsche, T. R., Jones, R. N. (2006). Accuracy of Three Automated Systems (MicroScan WalkAway, VITEK, and VITEK 2) for Susceptibility Testing of Pseudomonas aeruginosa against Five Broad-Spectrum Beta-Lactam Agents.. J. Clin. Microbiol. 44: 1101-1104 [Abstract] [Full Text]  
  • Moskowitz, S. M., Foster, J. M., Emerson, J. C., Gibson, R. L., Burns, J. L. (2005). Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother 56: 879-886 [Abstract] [Full Text]  
  • Macia, M. D., Borrell, N., Perez, J. L., Oliver, A. (2004). Detection and Susceptibility Testing of Hypermutable Pseudomonas aeruginosa Strains with the Etest and Disk Diffusion. Antimicrob. Agents Chemother. 48: 2665-2672 [Abstract] [Full Text]  
  • Moskowitz, S. M., Foster, J. M., Emerson, J., Burns, J. L. (2004). Clinically Feasible Biofilm Susceptibility Assay for Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis. J. Clin. Microbiol. 42: 1915-1922 [Abstract] [Full Text]  
  • Gibson, R. L., Burns, J. L., Ramsey, B. W. (2003). Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 168: 918-951 [Abstract] [Full Text]  
  • Miller, M. B., Gilligan, P. H. (2003). Laboratory Aspects of Management of Chronic Pulmonary Infections in Patients with Cystic Fibrosis. J. Clin. Microbiol. 41: 4009-4015 [Full Text]  
  • Saiman, L., Burns, J. L., Larone, D., Chen, Y., Garber, E., Whittier, S. (2003). Evaluation of MicroScan Autoscan for Identification of Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients. J. Clin. Microbiol. 41: 492-494 [Abstract] [Full Text]